KYNTRA BIO, INC. 10-Q

ITEM 5. OTHER INFORMATION. None. ITEM 6. E XHIBITS Exhibit Incorporation By Reference Number Exhibit Description Form SEC File No. Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation of FibroGen, Inc. 8-K 001-36740 3.1 11/21/2014 3.2 Amended and Restated Bylaws of FibroGen, Inc. S-1/A 333-199069 3.4 10/23/2014 4.1 Form of Common Stock Certificate. 8-K 001-36740 4.1 11/21/2014 4.2 Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014. S-1/A 333-199069 4.17 10/24/2014 10.1† Amendment No. 1 to Commercial Supply Agreement (Roxadustat) by and between FibroGen, Inc. and its Affiliates and Catalent Pharma Solutions, LLC dated as of January 1, 2023. 10-Q 001-36740 10.2 05/08/2023 10.2+ Offer Letter, dated July 23, 2023, between FibroGen, Inc. and Thane Wettig. 8-K 001-36740 10.1 07/25/2023 10.3+ Consulting Agreement, dated July 23, 2023, between FibroGen, Inc. and Enrique Conterno. 8-K 001-36740 10.2 07/25/2023 10.4*† Amended and Restated Exclusive License Agreement by and among FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd., and Eluminex Biosciences Suzhou) Limited, dated April 19, 2023. — — — — 86 Table of Contents 10.5*† Financing Agreement by and among FibroGen, Inc., certain of its subsidiaries, NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II Employees Fairview Holding LLC, and Wilmington Trust, National Association, dated as of April 29, 2023. — — — — 10.6*† Evaluation Agreement by and between FibroGen, Inc. and Fortis Therapeutics, Inc., dated May 5, 2023. — — — — 10.7*† Option Agreement and Plan of Merger by and among FibroGen, Inc., Fortis Therapeutics, Inc., and Shareholder Representative Services LLC, dated as of May 5, 2023. — — — — 31.1* Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). — — — — 31.2* Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). — — — — 32.1* Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1)). — — — — 101.INS Inline XBRL Instance Document: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document — — — — 101.SCH Inline XBRL Taxonomy Extension Schema Document — — — — 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document — — — — 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document — — — — 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document — — — — 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document — — — — 104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.) — — — — † Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential. + Indicates a management contract or compensatory plan. * Filed herewith 87 Table of Contents SIGNAT URES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FibroGen, Inc. Date: August 7, 2023 By: /s/ Thane Wettig Thane Wettig Interim Chief Executive Officer (Principal Executive Officer) Date: August 7, 2023 By: /s/ Juan Graham Juan Graham Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) 88